Nurse Practitioner Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Beverly Jaggers

Nurse Practitioner, Acute Care Bowling Green, KY Nurse Practitioner

NPI 1336636703 CMS profile 10653586

201 Park St, Bowling Green, KY 42101

Open in the dashboard

General payments

$3,671

222 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Beverly Jaggers of Bowling Green, KY is reported in the CMS Open Payments database as having received $3,671 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $246 13
2022 General $1,654 104
2021 General $1,771 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Beverly Jaggers
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Beverly Jaggers were reported at $0. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Beverly Jaggers Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,771 $123 $38–$327 $132
2022 $1,654 $130 $44–$369 $149
2023 $246 $144 $49–$410 $160
2024 $0 $146 $48–$433 $164
2025 $0 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $542 36 payments
  2. GlaxoSmithKline, LLC. $524 42 payments
  3. AstraZeneca Pharmaceuticals LP $348 15 payments
  4. Regeneron Healthcare Solutions, Inc. $260 18 payments
  5. Actelion Pharmaceuticals US, Inc. $259 15 payments
  6. Genzyme Corporation $204 9 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $161 8 payments
  8. Jazz Pharmaceuticals Inc. $143 8 payments
  9. Mylan Specialty L.P. $134 9 payments
  10. Inspire Medical Systems, Inc. $117 1 payment
  11. Other $979 61 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $3,642 219 payments
  2. Education $29 3 payments
Products named General payments · program years 2021–2023
  1. OFEV $310 20 payments
  2. TRELEGY ELLIPTA $285 24 payments
  3. DUPIXENT Inflammation And Immunology $260 18 payments
  4. FASENRA $260 7 payments
  5. BREZTRI $251 7 payments
  6. OPSUMIT $225 13 payments
  7. NUCALA $216 16 payments
  8. DUPIXENT Immunology $204 9 payments
  9. STIOLTO RESPIMAT $183 13 payments
  10. GLASSIA $161 8 payments
  11. Other $1,837 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

15

Median for Nurse Practitioner: 389

Drug cost

$98

Median for Nurse Practitioner: $21,885

Branded share of claims

0%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Montelukast Sodium Generic 15 $98

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record